Apimeds Pharmaceuticals US cash flow statement data for the quarter ended Jun 2026. This cash flow statement covers 10 quarters of results from Dec 2023 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Cash Flow Statement | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||
| Net Income | -0.30M | -0.45M | -0.33M | -0.31M | -0.40M | -2.67M | -1.79M | -7.22M | -9.48M | |
| Share-based Compensation | 0.21M | 0.21M | 1.70M | 0.71M | 1.81M | |||||
| Gains from Investment Securities | -0.01M | -0.01M | ||||||||
| Cash from Operations | -0.26M | -0.18M | -0.19M | -0.10M | -0.02M | -3.36M | -1.73M | -3.82M | ||
| Depreciation, Depletion & Amortization | ||||||||||
| Amortizatization of Intangibles | 0.02M | 0.01M | 0.02M | 0.06M | 0.03M | 0.01M | 1.00 | 0.24M | ||
| Change in Working Capital | ||||||||||
| Change in Accured Expenses | 0.01M | 0.24M | 0.11M | 0.18M | 0.34M | -0.82M | 0.45M | |||
| Other Working Capital Changes | -0.00M | -1.00 | -734.00 | -40.00 | 1.79M | 0.43M | 0.19M | |||
| Investing Activities | ||||||||||
| Capital Expenditures | 0.02M | 0.02M | ||||||||
| Cash from Investing Activities | -0.02M | -10.02M | ||||||||
| Financing Activities | ||||||||||
| Debt Issuance and Repayment | ||||||||||
| Long-Term Debt Issuances | 0.15M | 0.25M | 0.32M | -0.32M | 9.75M | |||||
| Change in Capital Stock | ||||||||||
| Net Shares Issued and Repurchased | 1.10M | |||||||||
| Net Equity Issued and Repurchased | -0.32M | |||||||||
| Misc. | ||||||||||
| Cash from Financing Activities | 0.15M | 0.08M | 0.27M | 11.86M | 8.49M | |||||
| Change in Cash | -0.26M | -0.08M | -0.04M | -0.02M | 0.25M | 8.48M | -1.75M | -5.35M | ||
| Free Cash Flow | -0.26M | -0.18M | -0.19M | -0.10M | -0.02M | -3.36M | -1.75M | -3.84M | ||
| Net Cash Flow | -0.26M | -0.18M | -0.04M | -0.02M | 0.25M | 8.50M | -1.75M | -5.35M |